Are you a bad boss?

Pharma execs share their tips for being a better leader.

By Taren Grom • Oct. 7, 2022

Her antibiotic company failed. Now she’s helping others avoid the same fate.

The chief of R&D at CARB-X explains why she believes small antibiotics companies can succeed despite market turmoil.

By Karissa Waddick • Oct. 6, 2022

Explore the Trendline➔

Commercialization, marketing and social media

As the pharma industry stares down a historic patent cliff, macroeconomic headwinds and challenging R&D costs for increasingly complex medicines, nailing the launch of new medicines has become increasingly critical. 

By PharmaVoice staff

C-suite shake-ups at 23andMe, Moderna signal new stages of growth

With their latest personnel moves, these life sciences companies are preparing for major business shifts.

By Karissa Waddick • Oct. 5, 2022

It’s electric — speeding up the cell therapy process for scalability

To improve the development of cell therapy-based treatments, many companies are turning to a technology that uses electric fields.

By Alexandra Pecci • Oct. 4, 2022

The 2 areas in life sciences most in need of talent

The industry is feeling the hiring crunch — here’s what pharma companies can do to mitigate the impact.

By Meagan Parrish • Oct. 4, 2022

To stay on the leading edge of oncology, AbbVie knows it has to take risks

In a field that has seen rapid progress but ongoing areas of unmet need, AbbVie is betting on emerging tech.

By Kelly Bilodeau • Oct. 4, 2022

Clinical trials haven’t harnessed the digital revolution — TransCelerate’s latest initiative aims to change that

The nonprofit’s VP of portfolio management discussed its “most transformative” digital initiative to date.

By PharmaVoice staff • Oct. 3, 2022

How do Biogen-Eisai’s two Alzheimer’s drugs stack up?

Biogen and Eisai's newest Alzheimer's success begs comparison to their past debacle — and bolsters the amyloid theory.

By Michael Gibney • Sept. 30, 2022

Woman of the Week: Pepper Bio’s Samantha Dale Strasser

The co-founder of Pepper Bio entered the biotech world three years ago with the goal of transforming drug discovery through the emerging discipline of transomics.

By Taren Grom • Sept. 28, 2022

Why precision medicine could be the next frontier in treating autism

Swiss-based Stalicla is banking on an AI-driven precision medicine discovery platform to deliver needed therapies in the autism space.

By Kelly Bilodeau • Sept. 27, 2022

Woman of the Week: Agilent Technologies’ Dr. Katharine Knobil

As the first chief medical officer of the diagnostic testing company, Dr. Katharine Knobil is focused on moving the science forward beyond precision oncology to liquid biopsy.

By Taren Grom • Sept. 14, 2022

Feds could soon bring COVID-style fight to superbug threat

COVID-19 has inspired renewed urgency in the need for weapons to combat antimicrobial resistant infections and new hope of government funding to meet the challenge.

By Karissa Waddick • Sept. 13, 2022

From the ‘go-go days’ to a bubble crunch — the biotech sector faces its next challenge

The highs of the sector in early 2021 gave way to a bear market that persisted into the second half of this year — but there's hope the bubble hasn't popped for good.

By Michael Gibney • Sept. 12, 2022

Woman of the Week: Foresite Capital’s Cindy Mesaros

The longtime marketing pro details her fascinating career journey and how she’s positioning early stage health companies to thrive. 

By Taren Grom • Sept. 7, 2022

Pharma’s renewed sickle cell investment lifts a once-shirked disease

Pfizer's $5.4 billion deal to acquire Global Blood Therapeutics invigorated the fast-growing market, and patients are fit to be the benefactors.

By Kelly Bilodeau • Sept. 1, 2022

First 90 Days: Adaptive Biotech’s Tycho Peterson

A long-time analyst, Tycho Peterson brings his business savvy to the C-suite at Adaptive, where he began as CFO in June with a knowledge of what works and what doesn't in the diagnostics space.

By Michael Gibney • Sept. 1, 2022

Moderna’s lawsuit against Pfizer and BioNTech explained in 10 quotes

The biotech says that its competitors’ COVID-19 vaccine copied proprietary mRNA technology. Here’s a breakdown of the case.

By Karissa Waddick • Aug. 31, 2022

Leading the industry’s next potential game-changer in drug discovery

Rachel Meyers, chief scientific officer at Faze Medicines, is helping guide the company towards the development of biomolecular condensates — an emerging field that could transform drug discovery.

By Alexandra Pecci • Aug. 29, 2022

Moderna, Eli Lilly and Schrödinger seek to boost financial and people strategies with key new hires

How the latest personnel shifts are impacting each company and the industry at large. 

By Karissa Waddick • Aug. 24, 2022

Patents, pandemics and pricing: a peek at the top drug from every big pharma

A look at how the biggest pharma companies in the world and their top-selling drugs fared in the first half of the year.

By Michael Gibney • Aug. 22, 2022

3 ways pharma can prep for Biden’s sweeping drug pricing policies

Now that Medicare will be able to negotiate drug prices under the Inflation Reduction Act, the industry can expect to see some changes. Here are some tips on how to navigate the changing tide.

By Karissa Waddick • Aug. 18, 2022

Inventing the COVID vax pill: a matter of convenience and durability

Recent data from Vaxart’s phase 1 trial of its COVID-19 inoculation pill shows potential.

By Kelly Bilodeau • Aug. 17, 2022

Right under our noses: Could COVID-19 vaccines be better as nasal spray?

Nasal vaccines under development by Codagenix, Xanadu Bio and others have the potential to finally help reduce virus transmission and breakthrough infections.

By Kelly Bilodeau • Aug. 16, 2022

As pharma M&A ramps up, U.S. execs are bullish on more deals

What top executives at Merck, Pfizer and more are saying about M&A as they move into the second half of the year.

By Michael Gibney • Aug. 11, 2022

4 ways to nail the launch of your cell therapy

A consultant’s view on how pharma companies should approach patient experience challenges when rolling out an autologous cell therapy.

By Meagan Parrish • Aug. 10, 2022